[MOL] new drug looks promising... [00395] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] new drug looks promising...



Medical Scientists To Begin Clinical Trials Of Promising Cancer
    Therapy
    [11/08/99; ScienceDaily]

CHAPEL HILL - Scientists at the University of North Carolina at
Chapel Hill are beginning phase one clinical trials, also known
as safety trials, of a promising new way of treating certain
cancers. 

In a study so far being done only at the UNC-CH School of Medicine,
the researchers will administer increasing doses of a compound
known as PS341 to between 20 and 30 cancer patients to determine
the highest doses they can receive without developing side effects.

Earlier work suggests that the compound will be safe and that
it might boost success in treating people with stubborn cases
of such blood-borne malignancies as leukemia, myeloma and lymphoma,
according to Dr. Robert Z. Orlowski, assistant professor of medicine.

"Everybody here is pretty excited about this compound because
it's being used experimentally at a few other universities for
solid tumors," said Orlowski, a member of the Lineberger Comprehensive
Cancer Center. "Although it is too early to tell how beneficial
it has been in shrinking solid tumors, clinicians have observed
few side effects. Our experimental data suggest it could be useful
in treating non-solid tumors, and that's why we're doing this
work." 

The full article can be found at:

http://www.sciencedaily.com/releases/1999/11/991108090639.htm
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------